How Ph.D. was paid
$11.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Emil D. Kakkis, M.D., Ph.D.President and Chief Executive Officer | $861,100 | $8,364,938 | $1,847,356 | $299,663 | $32,478 | $11,405,535 |
| Howard HornChief Financial Officer, Corporate Strategy and Executive Vice President | $604,385 | $2,241,463 | $663,134 | $227,625 | $14,000 | $3,750,607 |
| Erik HarrisChief Commercial Officer and Executive Vice President | $619,692 | $2,407,560 | $712,257 | $291,563 | $14,000 | $4,045,072 |
| Eric Crombez, M.D.Chief Medical Officer and Executive Vice President | $630,231 | $2,407,560 | $712,257 | $238,125 | $14,000 | $4,002,173 |
| Karah ParschauerChief Legal Officer and Corporate Affairs, Executive Vice President | $585,342 | $2,075,430 | $614,011 | $220,530 | $14,000 | $3,509,313 |
What changed and why
- $13.7MCEO total compensation decreased from $13,717,687 in 2024 to $11,405,535 in 2025.
- 68%The company received 68% support for its say-on-pay proposal at the 2025 annual meeting.
- 70%Stockholder outreach reached holders of approximately 70% of outstanding shares as of June 30, 2025.
- Enhanced transparency of the annual incentive program was adopted in response to stockholder feedback.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.